Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Innovent Biologics's share price for the quarter that ended in Jun. 2024 was $4.7075. Innovent Biologics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 1,628 Mil. Therefore, Innovent Biologics's market cap for the quarter that ended in Jun. 2024 was $7,666 Mil.
Innovent Biologics's quarterly market cap
increased
from Jun. 2023 ($6,147 Mil) to Dec. 2023 ($7,979 Mil) but then
declined
from Dec. 2023 ($7,979 Mil) to Jun. 2024 ($7,666 Mil).
Innovent Biologics's annual market cap
declined
from Dec. 2021 ($8,992 Mil) to Dec. 2022 ($6,575 Mil) but then
increased
from Dec. 2022 ($6,575 Mil) to Dec. 2023 ($7,979 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Innovent Biologics's Enterprise Value for Today is $7,804 Mil.
Innovent Biologics Market Cap Historical Data
The historical data trend for Innovent Biologics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innovent Biologics's Market Cap
For the Biotechnology subindustry, Innovent Biologics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Market Cap distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Market Cap falls into.
Innovent Biologics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Innovent Biologics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (OTCPK:IVBXF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Innovent Biologics Market Cap Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IVBXF has been successfully added to your 